Skip to main content
UCB's Global Corporate Website
instagram
facebook
twitter
youtube
linkedin
rss
Listen
3 Sep 2008
Vimpat® Approved in Europe
Read More
28 Aug 2008
UCB launches SHAPE, focusing on its Biopharma specialist efforts, and intends to reduce its world-wide workforce
Read More
1 Aug 2008
UCB reports financials in line with expectations, integration completed, R&D milestones achieved and stronger focus on core business
Read More
29 Jul 2008
UCB receives not-approvable letter from FDA for lacosamide for diabetic neuropathic pain
Read More
1 Jul 2008
UCB's Cimzia® filed with EMEA for treatment of rheumatoid arthritis
Read More
26 Jun 2008
UCB's Vimpat(TM) recommended for approval in Europe for epilepsy
Read More
24 Jun 2008
First results for Phase IIa data of UCB's lacosamide for treatment of fibromyalgia
Read More
10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra® and Cimzia® in Japan
Read More
6 Jun 2008
US FDA grants pediatric exclusivity for UCB's Keppra®
Read More
4 Jun 2008
UCB to implement full cold-chain for Neupro®
Read More
Pagination
First page
Previous page
‹ Previous
…
Page
87
Page
88
Page
89
Page
90
Current page
91
Page
92
Page
93
Page
94
Page
95
…
Next page
Next ›
Last page
Subscribe to
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
instagram
facebook
twitter
youtube
linkedin
rss